Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab.

MLA

Watson, Geoffrey Alan, et al. “Increase in Serum Choline Levels Predicts for Improved Progression-Free Survival (PFS) in Patients with Advanced Cancers Receiving Pembrolizumab.” Journal for Immunotherapy of Cancer, vol. 10, no. 6, June 2022. EBSCOhost, https://doi.org/10.1136/jitc-2021-004378.

APA

Watson, G. A., Sanz-Garcia, E., Zhang, W.-J., Liu, Z. A., Yang, S. C., Wang, B., Liu, S., Kubli, S., Berman, H., Pfister, T., Genta, S., Spreafico, A., Hansen, A. R., Bedard, P. L., Lheureux, S., Abdul Razak, A., Cescon, D., Butler, M. O., Xu, W., … Chen, E. (2022). Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. Journal for Immunotherapy of Cancer, 10(6). https://doi.org/10.1136/jitc-2021-004378

Chicago

Watson, Geoffrey Alan, Enrique Sanz-Garcia, Wen-Jiang Zhang, Zhihui Amy Liu, Sy Cindy Yang, Ben Wang, Shaofeng Liu, et al. 2022. “Increase in Serum Choline Levels Predicts for Improved Progression-Free Survival (PFS) in Patients with Advanced Cancers Receiving Pembrolizumab.” Journal for Immunotherapy of Cancer 10 (6). doi:10.1136/jitc-2021-004378.